Karin Hamberg
Directeur/Membre du Conseil chez LEO Holding A/S (Denmark)
Profil
Karin Jexner Hamberg is currently a Director at LEO Holding A since 2019.
She was previously the Chief Medical Officer & Executive Vice President at Veloxis Pharmaceuticals A in 2009.
She holds a doctorate degree from the University of Copenhagen.
Postes actifs de Karin Hamberg
| Sociétés | Poste | Début |
|---|---|---|
LEO Holding A/S (Denmark)
 LEO Holding A/S (Denmark) Financial ConglomeratesFinance LEO Holding A/S invests in company with interest in medical dermatology. The company was founded on November 29, 2017 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | 27/02/2019 |
Anciens postes connus de Karin Hamberg
| Sociétés | Poste | Fin |
|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Directeur Technique/Scientifique/R&D | 15/04/2009 |
Formation de Karin Hamberg
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
LEO Holding A/S (Denmark)
LEO Holding A/S (Denmark) Financial ConglomeratesFinance LEO Holding A/S invests in company with interest in medical dermatology. The company was founded on November 29, 2017 and is headquartered in Copenhagen, Denmark. | Finance |
